According to Baihua Pharmaceutical's announcement, the cumulative deviation value of the daily closing price increase of the company's stock exceeded 100% within 10 consecutive trading days, which is a serious abnormal fluctuation. In the first quarter of 2026, the company's revenue was 67.1829 million yuan, down 30.68% year on year, and net profit was 6.6427 million yuan, down 67.94% year on year. The stock price increase deviated seriously from the operation. Currently, the company's rolling price-earnings ratio is 203 times, far higher than 35.06 times that of the industry, and the turnover rate soared to 34.43% on August 12. The controlling shareholder has no major asset restructuring plans for the next 36 months, reminding investors to be aware of transaction risks.

According to Baihua Pharmaceutical's announcement, the cumulative deviation value of the daily closing price increase of the company's stock exceeded 100% within 10 consecutive trading days, which is a serious abnormal fluctuation. In the first quarter of 2026, the company's revenue was 67.1829 million yuan, down 30.68% year on year, and net profit was 6.6427 million yuan, down 67.94% year on year. The stock price increase deviated seriously from the operation. Currently, the company's rolling price-earnings ratio is 203 times, far higher than 35.06 times that of the industry, and the turnover rate soared to 34.43% on August 12. The controlling shareholder has no major asset restructuring plans for the next 36 months, reminding investors to be aware of transaction risks.